Eko Low Ejection Fraction Tool (ELEFT) vs Us2.v2
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (ELEFT) is a screening tool that integrates with digital stethoscopes to detect low ejection fraction during routine physical exams, aiding in early heart failure identification. Tool B (Us2.v2) is an AI-powered solution for automating the comprehensive interpretation and reporting of echocardiograms, covering multiple cardiac diseases. While both contribute to cardiac care, ELEFT focuses on initial, non-invasive screening, whereas Us2.v2 specializes in detailed diagnostic analysis of imaging studies.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Eko Low Ejection Fraction Tool (ELEFT) integrates with Eko digital stethoscopes during routine physical exams, providing a non-invasive screening tool for early detection of low ejection fraction in approximately 15 seconds. Us2.v2 automates the interpretation of full echocardiograms, delivering a complete structured report with measurements and disease detection, primarily aimed at reducing reporting time by up to 70% and increasing scan throughput for diagnostic purposes.
ELEFT is cloud-based software integrated with Eko digital stethoscopes, and while part of an enterprise platform, specific direct EHR integration details beyond cloud data processing and storage are not explicitly provided. Us2.v2 offers seamless integration with existing PACS, CVIS, or EMR systems, supporting both HL7 and DICOM SR for comprehensive data exchange.
ELEFT specifically aids in the early detection of low ejection fraction, a key indicator of heart failure, and is suitable for Cardiology, Family Medicine, and Internal Medicine for screening purposes. Us2.v2 automates the detection of cardiac amyloidosis, aortic stenosis, heart failure, pulmonary hypertension, and valvular disease, making it primarily beneficial for Cardiology specialists.
ELEFT is an FDA-cleared AI algorithm for early detection of low ejection fraction, with studies showing a sensitivity of 74.7% and specificity of 77.5% for LVEF u226440%. Us2.v2 provides 100% AI automation for echo interpretation, delivering guideline-adherent and explainable AI with transparent visual overlays and editable outputs to ensure accuracy and user understanding.
ELEFT integrates with routine physical exams using a familiar stethoscope, suggesting a relatively low learning curve for clinicians already using Eko digital stethoscopes. Us2.v2 automates complex echocardiogram interpretation, and while it eliminates manual tasks, its 'explainable AI with transparent visual overlays and editable outputs' suggests a learning process to review and potentially modify automated reports.
ELEFT is part of Eko's SENSORAu2122 platform, an enterprise solution, indicating it is designed for broader deployment across multiple sites. Us2.v2 offers custom pricing based on deployment options and features, with both cloud and on-premise options, providing flexibility for multi-site rollouts and integration with existing infrastructure.
More Comparisons
Backers
Who funded each tool's parent company.